The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation

The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation

EGFR-mediated tumors have been targeted to overcome several different malignant cancers. EGFR overexpression and mutations are directly related to the malignancy, which makes the therapy more complicated. One reason for the malignancy is the induction of AP1 followed by inflammation via IL-6 secreti...

Full description

Bibliographic Details
Main Authors:	Woo Jung Sung, Dohyang Kim, Anlin Zhu, Namki Cho, Hee Min Yoo, Ji Heon Noh, Kyoung Mi Kim, Hyun-Su Lee, Jaewoo Hong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	ErbB EGFR TKI lysosome combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1050758/full

Similar Items

Does EGFR Signaling Mediate Orexin System Activity in Sleep Initiation?
by: Marina Kniazkina, et al.
Published: (2023-05-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer
by: Jianjie Zhu, et al.
Published: (2021-06-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Análise da expressão imuno-histoquímica de c-erbB-2 e EGFR em carcinoma epidermóide de esôfago Immunohistochemical expression of c-erbB-2 and EGFR in esophageal squamous cell carcinoma
by: Yukie Sato, et al.
Published: (2007-08-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

The Signaling of Neuregulin-Epidermal Growth Factor Receptors and Its Impact on the Nervous System
by: Marzia Tagliaferro, et al.
Published: (2023-10-01)

Airway Epithelial Dysfunction in Asthma: Relevant to Epidermal Growth Factor Receptors and Airway Epithelial Cells
by: Hideki Inoue, et al.
Published: (2020-11-01)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2022-05-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
by: Martina S. J. McDermott, et al.
Published: (2019-02-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Influence of human HB-EGF secreted form on cells with different EGFR and ErbB4 quantity
by: O. I. Krynina, et al.
Published: (2019-10-01)

High Levels of Receptor Tyrosine Kinases in CCM3-Deficient Cells Increase Their Susceptibility to Tyrosine Kinase Inhibition
by: Miriam Sartages, et al.
Published: (2020-12-01)

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs
by: Louise Pinet, et al.
Published: (2021-11-01)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
by: Jin-Soo Kim, et al.
Published: (2023-09-01)

Detección de mutaciones del gen EGFR en ADN circulante por medio de biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas: Revisión rápida
by: Virgilio E Failoc-Rojas
Published: (2021-08-01)

The under-appreciated promiscuity of the epidermal growth factor receptor family.
by: Sean P Kennedy, et al.
Published: (2016-08-01)

Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
by: Marco Macagno, et al.
Published: (2011-08-01)

Biotecnología para el estudio de enfermedades neuropsiquiátricas y la búsqueda de nuevos tratamientos: caso de las neuregulinas
by: María Clara Soto-Bernardini
Published: (2019-09-01)

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
by: Yajie Cheng, et al.
Published: (2022-08-01)

Overexpression of ErbB-1 (EGFR) Protein in Eutopic Endometrium of Infertile Women with Severe Ovarian Endometriosis during the ‘Implantation Window’ of Menstrual Cycle
by: Jeevitha Poorasamy, et al.
Published: (2022-10-01)

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells
by: Anne Kiefer, et al.
Published: (2024-01-01)

Oxygen Tension Regulates Lysosomal Activation and Receptor Tyrosine Kinase Degradation
by: Jaewoo Hong, et al.
Published: (2019-10-01)

Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
by: Andrew J. Shih, et al.
Published: (2011-03-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-03-01)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
by: Kiran Munawar, et al.
Published: (2022-11-01)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
by: Sook-hee Hong, et al.
Published: (2022-12-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Bispecific Antibodies for IFN-β Delivery to ErbB2<sup>+</sup> Tumors
by: Vladislav S. Rybchenko, et al.
Published: (2021-12-01)

Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
by: Sandrine Faivre, et al.
Published: (2013-03-01)

Apelin signaling dependent endocardial protrusions promote cardiac trabeculation in zebrafish
by: Jialing Qi, et al.
Published: (2022-02-01)

The expression of HER2/neu in patients with lung cancer and its associated factors
by: Mohammadreza Lashkarizadeh, et al.
Published: (2023-02-01)

Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies
by: Miguel A. Ortega, et al.
Published: (2022-03-01)

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
by: Camilla Palumbo, et al.
Published: (2023-02-01)

Emerging Role of Oxidative Stress on EGFR and OGG1-BER Cross-Regulation: Implications in Thyroid Physiopathology
by: Carmelo Moscatello, et al.
Published: (2022-02-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
by: Kamal Eltayeb, et al.
Published: (2022-01-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
by: Min-Kyung Yeo, et al.
Published: (2022-06-01)

Impacto na Sobrevida Livre de Progressão pela Falta de Acesso a Inibidores de EGFR em Carcinoma de Pulmão de Células não Pequenas no Sistema de Saúde Público Brasileiro
by: Gabriel Lenz, et al.
Published: (2018-03-01)